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Abstract 
3-O-sulfotransferase enzyme (sHS) from Litopeneaus vannamei was cloned and its 
substrate specificity was investigated against a number of GAG structures, including 
modified heparin polysaccharides and model oligosaccharides. For the heparin 
polysaccharides, derived from porcine intestinal mucosa heparin, sulfate groups were 
incorporated into glucosamine residues containing both N-sulfated and N-acetylated 
substitution within regions of the predominant repeating disaccharide, either I-ANS or I-
ANAc. However, the resulting polysaccharides did not stabilize antithrombin, which is 
correlated with anticoagulant activity. It was also shown that the enzyme was able to 
sulfate disaccharides, I2S-ANS and G-ANAc. The results further illustrate that 3-O-
sulfation can be induced outside of the classical heparin-binding pentasaccharide 
sequence, show that 3-O-sulfation of glucosamine is not a sufficient condition for 
antithrombin stabilization and suggest that the use of this enzyme during HS 
biosynthesis may not occur as the final enzymatic step. 
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 Heparan sulfate (HS) and heparin are sulfated glycosaminoglycans (GAG) 
composed of repeating disaccharide units of (14)-linked α-D-glucosamine and uronic 
acid. Whereas HS disaccharides are predominantly formed by β-D-glucuronate and α-
D-glucosamine that can be either N-acetylated or N-sulfated, heparin is more sulfated, 
composed mainly of α-L-iduronate 2-O-sulfate and α-D-glucosamine N,6 sulfate 1. 
These modifications occur in the Golgi apparatus via a series of N-deacetylases/N-
sulfotransferase (NDST), sulfotransferases and a C5-epimerase. HS and heparin 
biosynthetic processes were first described by Lindahl in 1977 2 and since then it has 
been assumed that the enzymatic processing, ultimately resulting in unique 
substitution patterns, occurs through a hierarchical sequence of enzymatic events 2 
where NDST is followed by C5-epimarese, 2-O-sulfotransferase, 6-O-sulfotranferase 
and, lastly, 3-O-sulfotransferase. 
The presence of HS biosynthesis enzymes in organisms is related strongly to 
the emergence of multicellularity and tissue organization, being a characteristic of 
eumetazoan lineage 3, 4. Moreover, a correlation between the complexity of an 
organism and the number of HS sulfotransferase isoforms is evident. For instance, the 
primitive organism C. elegans has just one isoform for each of the five known 
sulfotransferases, while humans have four NDSTs, one C5-epimerase, one HS2ST, 
three HS6STs and seven HS3STs 3. Interestingly, rudimentary HS biosynthesis 
enzymes were found in unicellular and colony-forming organism M. brevicollis, 
suggesting that GAGs could have a key role in the emergence of multicellularity 
through extracellular organization and establishment of cell-cell communication 3. 
HS and heparin are known to regulate a wide range of physiological processes 
5 and heparin is employed for its pharmacological activity in cardiovascular medicine 
as an anticoagulant and antithrombotic drug 6 since it modulates antithrombin (AT), the 
principal physiological inhibitor of the coagulation in vertebrates. The sequence in 
heparin which is thought principally responsible for this activity corresponds to a 
pentasaccharide ANAc/NS,6S-G-ANS,3S,6S-I2S-ANS,6S (AGA*IA), found on average in one-
third of the heparin chains 7. This specific sequence was described following 
fractionation of heparin by affinity chromatography, which revealed that AT high-affinity 
fractions had 3-O-sulfated glucosamine 8. From then on, this modification has been 
considered the key for AT-binding 9, 10, since pentasaccharide sequences lacking 3-O-
sulfated glucosamine have decreased in affinity for AT 10, even though the presence 
of 3-O-group in central glucosamine is not essential to activate AT 9 since other GAGs 
and non-GAG based structures are able to activate AT 11, 12. 
Despite being unique and responsible for high-affinity AT-binding, different 
sequences and compounds, even non-carbohydrates, can exert the same effect 12-14. 
Furthermore, it is also important to highlight that under normal physiological conditions 
there is little circulating heparin, indicating that its biological function should be 
distinguished from its pharmacological use 1. Furthermore, 3-O-sulfated glucosamine 
is yet to be found within commonly purified HS. 
HS3ST is the largest sulfotransferase family in humans, although the simplest 
organism in which this enzyme has been reported is M. brevicollis 3 suggesting that, 
evolutionarily, 3-O-sulfated glucosamine could be the most ancient and has played an 
important role in the emergence of cellular communication. In addition, species that 
lack AT-mediated coagulation have heparin-like molecules containing high levels of 3-
O-sulfated glucosamine with negligible anticoagulation activity 15-18. These data bring 
to light questions regarding the importance of the 3-O-sulfate group in AT activation 
and its role regarding the biological functions of HS.   
In a previous study, a heparin-like polysaccharide from the shrimp L. vannamei 
exhibited a higher proportion of 3-O-sulfated glucosamine (A*) than mammalian 
heparin, however, this compound presented low anticoagulation activity 18. Here, in 
order to better understand the role of 3-O-sulfotransferase in HS/heparin biosynthesis, 
the cloning, expression of 3-O-sulfotransferase from L. vannamei and an investigation 
into substrate recognition are reported. 
 




[35S]PAPS (3’Phosphoadenosine-5’phosphosulfate-[35S], 2,3Ci/mmol) was purchased 
from Perkin Elmer NEM (Waltham, MA, USA). Hyaluronic acid sodium salt (HA, from 
Strecococcus sp) was purchased from Merck Millipore (Kenilworth, NJ, USA). 
Chondroitin 4-sulfate (C4S, from bovine trachea), chondroitin 6-sulfate (C6S, from 
shark cartilage) and dermatan sulfate (DS, from porcine mucosa) were obtained from 
Sigma-Aldrich Co (St, Louis, MO, USA). Heparan sulfate (HS) from bovine pancreas 
was prepared according to 19. Heparin (Hep) from porcine mucosa was obtained from 
Bioiberica S.A. (Barcelona, Catalunya, Spain), while chemically modified heparins 
were prepared as described in 20. The two oligosaccharides were synthetized as 
described in 21.   
 
2. Litopeneaus vannamei sulfotransferase (sHS) cloning   
To clone the sulfotransferase (sHS) from shrimp L. vannamei, the expressing 
sequence tag (EST), named Contig 7734-v1, from The Marine Genomics Project 
database (http://mgnew.clemson.edu/) was used. This EST was used because it 
showed similarity to human HS3ST1 and HS3ST5 by Blastx from NCBI 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). Thus, a portion of the Contig 7734-v1 was 
used as a primer to amplify the catalytic domain of the enzyme from L. vannamei using 
the SMARTer Race 5’/3’ Kit. The coding-sequence obtained was performed according 
to the manufacturer´s instructions. Finally, it was PCR-amplified using forward primer 
(5´GAAGATCTTCCGGAGGCTGCCCCAA 3´) and reverse primer 
(5´GAATTCGAACTTCAGCTGGCCTTAACG 3´). The PCR product was purified by 
agarose electrophoresis after digestion with BglII and EcoRI endonucleases enzymes, 
cloned in pRSET A and transformed into E. coli BL21 pLysS competent cells. The 
coding-sequence from shrimp was confirmed by Sanger sequencing in an Applied 




3. Protein expression and purification 
After induction with 1mM IPTG, the protein expression was carried out in LB medium 
at 37°C for 1h and 200 rpm. The bacterial pellet was suspended in 10 mL of lysis buffer 
(50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 1 mg/mL of lysozyme), incubated in ice for 
30min and sonicated on ice using six 30-second bursts. Lysed cells were centrifuged 
(4000 x g for 20min, 4°C) and the supernatant was applied to a HisTrap HP column 
(GE Healthcare), previously equilibrated with native binding buffer (50 mM NaH2PO4, 
pH 8.0, 500 mM NaCl, 10 mM imidazole). The column was exhaustively washed with 
native wash buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, and 40 mM imidazole) 
and the recombinant protein was eluted with native elution buffer (50 mM NaH2PO4, 
pH 8.0, 500 mM NaCl, 250 mM imidazole). Fractions were pooled and buffer-
exchanged to phosphate-buffered saline using PD-10 desalting column (GE 
Healthcare). The recombinant protein was stored at -20°C. 
 
4. In silico analysis 
The similarity of HS/Hep sulfotransferases from human to the cloned-sequence from 
the L. vannamei was analyzed by MUSCLE (Multiple Sequence Alignment) from 
EMBL-EBI (http://www.ebi.ac.uk/Tools/msa/muscle/). Furthermore, structure protein 
prediction was performed using PHYRE2 Protein Fold Recognition Server program 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi? id=index). 
 
5. Recombinant sHS activity assay 
 
5.1 Glycosaminoglycan substrate 
Sulfotransferase activity was determined by incubating 40 µL of purified recombinant 
enzyme (0.05 µg/µL) with 100 µg of acceptor substrates and 50000 cpm [35S]PAPS in 
100 µL of reaction buffer (50mM Imidazole, pH 7.0, 0.025 µg/µL protamine sulfate, 1 
mM dithiothreitol). Acceptor substrates were HS, heparin (Hep), modified heparin: O,N-
desulfated-N-reacetylated (HepNAc), O,N-desulfated-N-resulfated (HepNSulfo), N-
desulfated-N-reacetylated Heparin (HepdNSrNAc), C4S, C6S, DS and HA. Reactions 
were incubated at 37°C overnight and stopped by heating at 100°C for 1min. The 35S-
labeled products were examined by agarose gel electrophoresis. 
 
 
5.2 Oligosaccharides substrates 
The activity of sHS was also analyzed using two oligosaccharides (G-ANAc and I2S-ANS) 
as acceptor substrates in order to confirm the specificity of recombinant enzyme to 
heparan sulfate/heparin sequence and whether HS/Hep biosynthesis occurs under the 
hierarchical model. The reaction mixture contained 50 mM MES, pH 7.0, 10 mM MnCl2, 
5 mM MgCl2, 0.5 µg of oligosaccharide, 50000 cpm [35S]PAPS and 80 µL of 
recombinant enzyme in a final volume of the 200 µL. After incubation at 37°C overnight, 
the reaction was stopped by heating at 100°C for 1min. In the negative control of each 
reaction, enzyme was substituted by water. 35S-labeled products were 
chromatographed in 500 µL DEAE-Sepharose using NaCl gradient 0.02 - 2 M for 22 
mL with a flow of 0.250 µL/min in an ÄKTA purifier system (GE Healthcare). Fractions 
(500µL) were collected and the quantity of 35S-sulfated oligosaccharide was measured 
by liquid scintillation counting. The values for the blank reaction were subtracted from 
each run. 
 
6. Agarose gel electrophoresis (PDA) 
All reactions products were submitted to agarose gel electrophoresis as previously 
described by Dietrich and Dietrich, 1976 22. Briefly, 25 µg of each acceptor (5 µL) was 
applied to a 0.55% agarose gel in 0.05 M 1,3-diaminopropane-acetate buffer, pH 9.0 
and subjected to electrophoresis at 100 V for 1h. The gels were fixed with 0.1% 
cetyltrimethylammoinum bromide (CETAVLON) solution for 2h, dried and stained with 
toluidine blue solution (0.1% toluidine blue in 1% acetic acid in 50% ethanol), destained 
with 1% acetic acid in 50% ethanol solution. Subsequently, the gels were exposed for 
three days to radiation sensitive films and developed in Cyclone Storage Phosphor 
System (Packard Instrument Company INC., Groningen, Netherlands). 
 
7. NMR spectroscopy 
Prior to NMR experiments, the 35S-labeled HepNSulfo was purified. Briefly, to the 
sample was added trichloroacetic acid 90% (10% of sample volume) and, after 30 min 
on ice, the sample was centrifuged and the supernatant was collected. 2 volumes (v/v) 
of methanol were added and, after 24h at -20 °C, the precipitate formed was collected 
by centrifugation (10000 x g for 15min at 4 °C), dried and suspended in 0.5 mL 
deuterium oxide (D99.99%, Aldrich Chemistry, St. Louis, MO, USA) containing 0.006% 
TSP 3-(trimethylsilyl)proprionic -2,2,3,3-d4 acid). The spectra were obtained in the 
Superconducting Fourier NMR Spectrometer AVANCE III 600 MHz, Bruker 
Corporation using the Triple Resonance Broadband Inverse (TBI) probe, at Instituito 
de Química, Unicamp, Campinas, SP, Brazil. 
 
8. Differential scanning fluorimetry (DSF)   
The capacity of 35S-labeled products to stabilize antithrombin was analyzed as 
described by Lima et al., 2013 11. Human antithrombin (AT) (1 mg/mL), previously 
purified from citrate plasma on a heparin-Sepharose column, was incubated with 
different substrates in the presence of SyproOrangeTM dye (Invitrogen). Firstly, the dye 
was diluted in water (1 sypro:50 water (v/v)) and 3.5 µL was added to the mixture 
reaction in PBS buffer. The dye has an excitation wavelength of 300 nm or 470 nm and 
emits at 570 nm when bound to hydrophobic residues. Different substrates used were 
25 µg of unfractionated heparin (UFH) (10 mg/mL), 62.5 µg of Arixtra pentasaccharide 
(ANS,6S-G2OH-ANS,6S,3S-I2S-ANS,6S-OMe) (12.5 mg/mL), 25 µg of each modified heparin 
and 25 µg of 35S-labeled modified heparins, previously analyzed by PDA. Reactions 
were incubated at 31°C for 2 min, and, then they were subjected to a step-wise 
temperature gradient from 32 to 85°C in a 0.5°C steps. Between each temperature 
step, there was a 5s incubation period to equilibrate samples. Reactions were 
developed at 7500 Real Time PCR System (Applied Biosystems) in triplicate. The final 




Phylogenetic analysis of sHS from Litopenaeus vannamei  
 
After cloning and sequencing the sHS from shrimp, the amino acid sequence was 
predicted using Expasy software: SIB Bioinformatics Resouce Portal through the 
Translate tool (Figure 1A and S1). Figure 1 shows the sHS domains responsible for 
the carbohydrate and PAPS binding, which are shown in red in the cloned region. 
Furthermore, comparative analyses were performed, including all HS sulfotransferases 
from Homo sapiens. These nucleotide and amino acid sequences were obtained from 
PubMed-NCBI and UniProteinKB databases respectively and aligned using MUSCLE 
(Figure 1B and 1C). The analysis showed that the heparan sulfate 3-O-
sulfotransferase family from Homo sapiens (hHS3ST) exhibited homology with sHS, 
the isoforms 1 and 5 being the closest, and are those thought to be responsible for 
anticoagulant HS production. Protein 3D structure was modeled using PHYRE2 
Protein Fold Recognition Server, shown in Figure 1D, which highlights the significant 
structural similarity between sHS and the human heparan sulfate 3-O-sulfotransferase 
isoform 5. 
 
Substrate selectivity for sHS 
 
a. Broad selectivity assays 
Heparan sulfate 3-O-sulfotransferase transfers sulfate from PAPS (adenosine 3′-
phosphate 5′-phosphosulfate) to the specific 3-OH position of a glucosamine to 
generate 3-O-sulfated heparan sulfate. The activity assay was based on the transfer 
of radioactive sulfate from PAP[35S] to selected substrates. First, we tested the 
substrate selectivity of sHS towards various glycosaminoglycans. Only chemically 
modified heparins served as substrates for sHS (Figure 2A) whereas chondroitin 4-
sulfate, chondroitin 6-sulfate, dermatan sulfate and hyaluronic acid did not (Figure S2), 
indicating that the sHS modifies only HS/heparin. Nonetheless, absence of 
radioactivity in HS and heparin may suggest that the 3-OH sites were already modified, 
resulting in null sHS action. Furthermore, since N-desulfated-N-reacetylated heparin, 
which would be the common substrate for NDST, was not modified by sHS, the 
recombinant enzyme from L. vannamei belongs to the O-sulfotransferase family. 
Figure 2A shows the activity assay on modified heparins where both sHS and 
recombinant human HS3ST5 were able to transfer sulfur to the chemically modified 
substrates, O,N-desulfated-N-resulfated and O,N-desulfated-N-reacetylated heparin. 
 
b. Determination of sulfation site by NMR 
Proton and carbon NMR chemical shifts of HepNSulfo, used as control, and 
HepNSulfo[35]S-sulfate, previously submitted to sHS action, were assigned by 
Heteronuclear Single Quantum Coherence spectroscopy (HSQC) experiments. The 
HepNSulfo[35]S-sulfate exhibited signals similar to those ascribed to the control. 
Nevertheless, only the HepNSulfo[35]S-sulfate showed a signal at 5.5/99.5 ppm that 
corresponds to ANS,6X,3S, indicating that sHS was able to transfer the sulfate from PAPS 
to C3-glucosamine (Figure 2B). 
 
3-O-sulfotransferase in the HS biosynthesis pathway 
 
a. Hierarchical vs non-hierarchical biosynthesis 
We further tested the sHS substrate recognition using two octasaccharides (G-ANAc 
and I2S-ANS) as substrates for the enzyme. As observed in Figure 3, both 
octasaccharides were modified by the sHS and, together with our previous findings, 
shows that sHS does not require either 2-O-, 6-O- or N-sulfate in heparin/HS to modify 
the polymer and, surprisingly, N-acetylation does not block 3-O-sulfation as anticipated 
by the hierarchical biosynthetic process where 3-O-sulfation would happen as the final 
modification step 2. The data show that 3-O-sulfation can occur in distinct biosynthetic 
steps either being the last HS sulfotransferase on biosynthesis process or the first one 
in a non-hierarchical way, according to the oligosaccharides tested. 
 
b. Tree structure for 3-O-sulfation 
Studies employing chemoenzymatic approach have revealed that different isoforms of 
HS3ST could sulfate HS through different pathways in biosynthesis, since HS3ST1 
can only work after the 6-O-sulfation step, while HS3ST3 must precede the 6-O-
sulfation modification to generate the ANS,3S,6S glucosamine residue 14. In Figure 4, 
different 3-O-sulfated heparin structures are shown. The classical HS biosynthetic 
route is illustrated by the pentasaccharide production, which is synthetized through 
hierarchical sequence of enzymatic events (NDST  Epimerase  HS2ST  HS6ST 
 HS3ST) (Figure 4, sequence 1). Indeed, the hierarchical pathway encapsulates the 
pentasaccharide biosynthesis yet, other 3-O-sulfated structures found within 
mammalian heparin cannot (Figure 4, sequences 2 and 3) 23. Furthermore, sequences 
from invertebrates of higher proportions of 3-O-sulfation, within “unusual” saccharide 
sequences and devoid of anticoagulant properties have been found (Figure 4, 
sequences 4 and 5) 16, 18. A tree structure for the biosynthesis of the major heparin and 
HS disaccharides has been proposed 24. Here, this scheme is expanded and, again, 
shows that heparin and HS biosynthesis as a whole cannot be described fully using 





Thermostabilizing effects of sHS-treated heparins  on AT 
As described by Lima et al, 2013 [22], the anticoagulant activity of heparin is correlated 
with the extent to which the complex between the polysaccharide and AT is stabilised, 
rather than by the secondary structural changes induced in AT by heparin binding. In 
order to analyze whether the addition of 3-O-sulfate groups induced further AT 
stabilization, AT was incubated with a range of different substrates and 
thermostabilization was measured using differential scanning fluorimetry (DSF) (Figure 
5). Only unfractionated heparin (UFH) and the pentasaccharide sequence, classical 
anticoagulant drugs, stabilized AT (61,75°C and 65,75°C respectively) whereas 
heparins[35]S-sulfate, previously modified by sHS, were unable to do so (Figure 5). This 
shows that a 3-O-sulfate group can be introduced into the polysaccharide but, this does 




The first description of 3-O-sulfated glucosamine residues in heparin were 
suggested by Danishefsky et al., 1969 25 when, according to methylation analyses, the 
authors proposed that heparin contained small proportions of 3,6-di-O-
sulfoglucosamine. Owing to the fact that 3-O-sulfation is a rare modification in heparin 
26 and also in HS 27 coupled to the absence of widely available methodologies able to 
evaluate such a modification, it is challenging to determine the real role and extent of 
this modification in HS and heparin biosynthetic and biological properties. 
Since the discovery of 3-O-sulfate groups in heparin with high-affinity for 
antithrombin 8, this modification has been considered crucial to the pharmacological 
role of heparin since the presence of 3-O-sulfation in the central glucosamine of the 
pentasaccharide (AGA*IA) increases 1000-fold the heparin binding for AT 10. 
Nonetheless, besides the presence of 3-O-sulfated glucosamine, several other 
structural features of heparin have been reported to influence in AT activity 10, 14, 28-30.  
In this study, we cloned and characterized a sulfotransferase from the shrimp L. 
vannamei similar to the isoforms 1 and 5 from Homo sapiens. The results suggest that 
this cloned enzyme is able to transfer sulfate to C3 position of glucosamine and, since 
these isoforms are responsible for their production 31, 32, also produce anticoagulant 
polysaccharides. The identity of the 3-O-sulfotransferase was confirmed by 
radiolabeling activity assays and NMR spectroscopy. 
 According to the classical HS biosynthesis 33, HS chain modification occurs 
hierarchically, meaning that 3-O-sulfotransferase is the last enzyme to modify the HS 
chains. Nevertheless, both HepNAc or G-ANAc compounds, which show only N-
acetyated glucosamine in their structure, were modified by sHS, indicating that the HS 
sulfotransferases could act on substrates independent of this sequential route 14, 24, 
which emphasizes that 3-O-sulfotransferase works at different steps of the biosynthetic 
process. It is important to highlight that organisms such as M. brevicollis, which were 
the first organisms to exhibit HS sulfotransferases, have only HS2ST and HS3ST. 
Furthermore, it has also been suggested that the epimerase enzyme appears 
evolutionarily later in a development 3. Hence, 3-O-sulfated heparin/HS can be 
biosynthesized through different pathways.  
It has been demonstrated that the high affinity of heparin towards AT requires a 
pentasaccharide sequence that contains a 3-O-sulfate group in a central glucosamine 
unit 10, 34. However, our results show that the 3-O-sulfated chemically modified heparins 
were not able to further stabilize AT, compared to their untreated counterparts, 
suggesting that the presence or abundance the 3-O-sulfation is not, in itself, sufficient 
to provide anticoagulant activity 9, 18. One may argue that the 3-O-sulfation of the 
studied polysaccharides is too low to promote AT stabilization but it is important to 
highlight that these modification themselves, even within pharmaceutical heparins, are 
indeed low and, in our work, they were high enough to be detected by NMR, that is, at 
least 2-3%. Moreover, previous studies have already shown that the presence of 3-O-
sulfated groups in heparan is not essential for normal hemostasis, since Hs3t1-/- 
knockout mice did not exhibited a pro-coagulant phenotype 35, questioning the role of 
this modification: other heparin features are relevant for such events 18. 
In summary, our data show that 3-O-sulfate groups are not solely responsible 
for AT stabilization and that 3-O-sulfotransferases can work in a non-hierarchical 
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Figure 1: Composite DNA, predicted amino acid sequences and structural model for the 
shrimp Litopeneaus vannamei sulfotransferase. (A) The nucleotide fragment as well as the 
amino acid sequence in red are related to enzymatic domains responsible for the carbohydrate and 
PAPS binding. This cDNA sequence (red) was cloned in pRSET A. Amino acid sequence was 
predicted using by Expasy (http://web.expasy.org/translate/). (B) Cladogram analysis of DNA 
sequences demonstrate that the isoforms 1 and 5 of 3-O-sulfotransferase (HS3ST) from Homo 
sapiens display higher identity to sHS. (C) Cladogram analysis of amino acid sequences confirms 
the highest similarity is among isoforms 1 and 5 of HS3ST to sHS. (D) Comparison between tertiary 
structures of sHS from shrimp L. vannamei (red) and HS3ST5 from Homo sapiens (blue). The 3D 
structure of sHS was modeled based on the human 3-O-sulfotransferase isoform 5 crystal structure 
(PDB #3BD9) using SWISS-MODEL 36. Structural alignment was performed on The PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC. Abbreviations: NDST: N-Deacetylase/N-
sulfotransferase; HS2ST: 2-O-sulfotransferase; HS3ST: 3-O-sulfotransferase; the isoforms of each 


























Figure 2: sHS substrate selectivity. (A) Activity assay on modified heparins. 1, 3 and 5: Substrate 
used was O,N-desulfated-N-resulfated heparin (25 µg of uronic acid); 2, 4 and 6: using as the 
substrate O,N-desulfated-N-reacetylated heparin (25 µg of uronic acid). In 1 and 2, the reaction 
mixture did not have the recombinant enzyme in their preparations. Left: PDA gel stained with toluidine 
blue. Right: PDA gel exposed for three days to radiation sensitive films. Both sHS enzyme as well as 
recombinant human HS3ST5 were able to transfer [35]S-sulfate to chemically modified heparins. M: 
Mixture of standard glycosaminoglycans containing chondroitin sulfate (CS), dermatan sulfate (DS) 
and heparan sulfate (HS) (5 µg each). (B) Description of compound HepNSulfo[35]S-sulfate, previously 
modified by sHS, by two-dimensional heteronuclear (HSQC) NMR. The HepNSulfo control (blue) and 
the HepNSulfo[35]S-sulfate (red) spectra displayed similiar components, whereas the HepNSulfo[35]S-
sulfate showed the presence of 3-O-sulfated glucosamine (ANS,6X,3S), indicating that sHS is indeed a 
3-O-sulfotransferase. Abbreviations: I: iduronic acid, ANS: glucosamine N-sulfated and ANS,6X,3S: 

































Figure 3: Analysis of 3-O-sulfation oligosaccharides by sHS. [35]S-sulfate products were 
analyzed using DEAE-Sepharose column and the 35S radioactivity was measured by liquid 
scintillation counting. (A) The oligosaccharide Glc-GlcNAc was used as substrate for the 
reaction. (B) The oligosaccharide IdoA2S-GlcNS was acceptor for the sHS activity reaction. The 




Figure 4: Different 3-O-sulfated heparin sequences found in animals and produced chemoenzymatically. (1) A minimum sequence of 
heparin (pentasaccharide) involved in AT-binding. It has been proposed that the pentasaccharide is synthesized according to the classical 
biosynthetic pathway, in which the enzymatic events happen through a hierarchical sequence, as described by Lindahl, 1977 2. (2 and 3) 
Sequences present in heparin described in Lindahl, 1994  23. (4) Heparin sequence found in clams that does not correlate with affinity for AT 16. 
(5) Sequence described in shrimp L. vannamei that has negligible anticoagulant activity despite its high affinity for AT and unusually higher 
proportion of 3-O-sulfated residues 18. (6 and 7) Scheme for 3-O-sulfated heparin sequences described by this study. The starting material for 
chemical modifications were porcine intestinal mucosa heparin, the schemes show iduronate rather than glucuronate once heparin does have 
significant higher proportions of iduronate. (8 and 9) Different oligosaccharide substrates required by HS3ST isoforms. While HS3ST3 must 

















Figure 5: Antithrombin stabilization assay with substrates modified by sHS. UFH 
(unfractionated heparin) and pentasaccharide (Arixtra™) were used as positive control, since 
they are already described as anticoagulant drugs. AT was incubated with different substrates 
and subjected to a step-wise temperature gradient. The melting temperatures for each condition 
are shown. Only the UFH and the pentasaccharide were able to stabilize AT, whereas none of 
the compounds (HepNSulfo[35]S-sulfate and HepNAc[35]S-sulfate) modified by the sHS and their 
counterpart (HepNSulfo and HepNAc) did. 
 
 
 
 
 
 
 
 
 
 
 
